Skip to main content

Table 2 Antiviral activity (IC50) and cytotoxicity (CC50) of NYAD-201, NYAD-202 and NYAD-203 in laboratory-adapted and primary HIV-1 isolates

From: Antiviral activity of α-helical stapled peptides designed from the HIV-1 capsid dimerization domain

  HIV-1 virus Subtype Cell Type Coreceptor IC50 (μM±SD)
      NYAD-201 NYAD-202 NYAD-203
Laboratory Strains IIIB B MT-2 X4 4.29 ± 0.62 2.36 ± 0.33 6.29 ± 0.54
  MN B MT-2 X4 3.03 ± 0.61 2.47 ± 0.71  
  SF2 B MT-2 R5X4 5.06 ± 1.37 4.48 ± 0.84  
  RF B MT-2 X4 2.84 ± 0.63 2.64 ± 0.39  
  BaL B PBMC R5 4.73 ± 1.92 2.23 ± 0.44  
  89.6 B PBMC R5X4 5.21 ± 0.87 3.47 ± 0.22  
RT-Resistant Isolate AZT-R B MT-2 X4 8.0 ± 1.27 4.53 ± 1.19 11.1 ± 3.82
PR-Resistant Isolate HIV-1 RF/L-323-12-3 B MT-2 X4 5.6 ± 0.5 3.5 ± 0.6  
Primary isolates 93RW024 A PBMC R5X4 9.88 ± 0.3 3.71 ± 0.19  
  92UG029 A PBMC X4 7.88 ± 1.01 3.97 ± 0.47  
  92US657 B PBMC R5 6.72 ± 0.98 3.61 ± 0.57  
  93IN101 C PBMC R5 1.58 ± 0.57 5.53 ± 0.39  
  98CN009 C PBMC R5 5.31 ± 0.83 4.08 ± 0.92  
  CMU02 EA PBMC X4 7.36 ± 0.69 4.2 ± 0.01  
  93BR020 F PBMC R5X4 2.78 ± 0.57 2.51 ± 0.43  
  RU570 G PBMC R5 7.48 ± 1.21 6.34 ± 2.22  
  BCF02 (Group 0) PBMC R5 15.84 ± 3.43 6.2 ± 1.2  
  Peptides CC 50 (μM) in MT-2 CC 50 (μM)in PBMC
  NYAD-201 >115 >115
  NYAD-202 30.2 ± 4.32 >116
  NYAD-203 13.24 ± 0.5 15.96 ± 1.47